

PRESS RELEASE

07 April 2025 13:00:00 CEST



Lipum AB (publ) has decided to postpone the Annual General Meeting for the financial year 2024 to June 16, 2025

The previous date for the Annual General Meeting for the financial year 2024 was May 14, 2025, but is now postponed to June 16, 2025.

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments

[**Lipum AB \(publ\) has decided to postpone the Annual General Meeting for the financial year 2024 to June 16, 2025**](#)